Mood & Balance

Why These Combine

Four compounds, each with its own trial literature on mood, and one caveat that outranks all of it: those trials were run in people with diagnosed depression or clinically significant stress, so this stack borrows evidence from clinical populations and is not a treatment for any of them. Saffron has the strongest-looking numbers. A meta-analysis of five randomised trials in adults with major depressive disorder found a large effect against placebo (effect size 1.62) and no difference against prescription antidepressants (Hausenblas 2013) — but the analysis pooled only five trials (two against placebo, three against antidepressants), two of its authors were consultants to a company marketing a saffron product, and the authors themselves asked for larger trials by research teams outside Iran before firm conclusions are drawn. Omega-3 comes with a formulation lesson: across 26 randomised trials and 2,160 participants the benefit on depression symptoms came from EPA-dominant products (at least 60% EPA, up to 1 g of EPA a day), while DHA-dominant products showed none (Liao 2019) — so for this slot, read the EPA line on the label, not the total. Ashwagandha's trial is about stress rather than mood: 64 chronically stressed adults who took 300 mg twice daily for 60 days scored lower on every stress scale and had lower serum cortisol than placebo (Chandrasekhar 2012); the 600 mg here is the same daily total, taken in the evening. Magnesium is the weakest link. The positive trial — 248 mg of elemental magnesium a day for six weeks improving PHQ-9 depression scores by six points in 126 adults — was open-label with no placebo (Tarleton 2017), and a systematic review of 18 magnesium-and-anxiety studies rated the overall evidence poor — and every study in it had recruited people already vulnerable to anxiety (Boyle 2017). Compared with the Stress Shield stack this takes ashwagandha in the evening and swaps rhodiola and phosphatidylserine for saffron and omega-3; compared with Deep Sleep it shares the magnesium but is aimed at the day, not the night. Verdict: saffron and an EPA-dominant omega-3 carry the evidence, ashwagandha is reasonable if stress is the driver, magnesium is a low-risk guess — and low mood that lasts more than a couple of weeks is a reason to see a clinician, not to add a fifth capsule.

• Stress rather than low mood? The Stress Shield stack takes the ashwagandha in the morning and adds rhodiola→
• If broken sleep is the real driver, start with the Deep Sleep stack — it shares the magnesium→
• What the saffron trials did and did not show — Saffron Extract and Mood→

References

1. 1.Hausenblas 2013, J Integr Med — Meta-analysis of 5 randomised controlled trials in adults with major depressive disorder: saffron vs placebo effect size 1.62 (p<0.001); saffron vs antidepressant effect size −0.15 (no difference); mean Jadad quality score 5. Authors call for larger trials by teams outside Iran. (clinical depression, not healthy adults; authors disclose an advisory role with a saffron-product company)
2. 2.Chandrasekhar 2012, Indian J Psychol Med — 64 adults with a history of chronic stress, randomised double-blind: 300 mg high-concentration full-spectrum ashwagandha root extract twice daily for 60 days reduced scores on all stress-assessment scales (p<0.0001) and serum cortisol (p=0.0006) versus placebo; adverse effects mild and comparable between groups.
3. 3.Liao 2019, Transl Psychiatry — Meta-analysis of 26 double-blind placebo-controlled trials (2,160 participants): omega-3 improved depression symptoms overall (SMD −0.28, p=0.004); EPA-pure and EPA-major (≥60% EPA) formulations at ≤1 g EPA/day showed benefit; DHA-pure and DHA-major formulations did not.
4. 4.Boyle 2017, Nutrients — Systematic review of 18 magnesium studies: benefit on subjective anxiety reported in 4 of 8 studies in anxious samples and 4 of 7 in PMS samples, none postpartum; no study used a validated stress measure; quality of existing evidence rated poor. (systematic review)
5. 5.Tarleton 2017, PLoS One — 126 adults with mild-to-moderate depression (PHQ-9 5–19), open-label randomised crossover: 248 mg elemental magnesium (as chloride) daily for 6 weeks improved PHQ-9 by −6.0 points (CI −7.9 to −4.2) and GAD-7 by −4.5 points versus no treatment; effects within two weeks; well tolerated. (open-label, no placebo arm)